



CQDM is pleased to announce the selection of letters of intent from its 2011-2012 Focus competition. The CQDM Strategic Orientation Committee has carefully examined all the projects using a very strict evaluation grid which takes into account all the criteria listed in our call for proposals. Given that CQDM is able to fund a limited number of projects, only those that best respond to the priorities and objectives of this program have been selected and are invited to submit a full proposal.

The list of the 9 selected projects is shown in the following table:

NAME OF PRINCIPAL INVESTIGATOR	AFFILIATION	PROJECT TITLE
Michael Buschmann	École Polytechnique de Montréal/Université de Montréal	Polymer-based nucleic acid delivery systems for siRNA delivery, protein expression from pDNA and antibody generation in cells and animal models: manufacturing process development and characterization of biological performance
Benoit Coulombe	Institut de recherches cliniques de Montréal/Université de Montréal	Mapping and systematic monitoring of protein interaction networks underlying insulin resistance to accelerate drug and biomarker discovery for type 2 diabetes
Philippe Gros	McGill University	A platform for the identification and valorization of novel validated targets for anti-inflammatory drug discovery
Sami Haddad	Université de Montréal	A generic and physiologically-based simulation software of drug disposition to advancing quantitative prediction of drug concentration in tumours and hence optimizing dose selection in chemotherapy
Richard Hoge	Université de Montréal	Magnetic resonance imaging of new metabolic and vascular biomarkers for Alzheimer's Disease
Ozzy Mermut	Institut National d'Optique	Multiplexing fluorescence lifetime imaging module for high content screening systems
Pierre Savard	École Polytechnique de Montréal/Université de Montréal	Development of two new medical devices for the diagnosis and follow-up of articular cartilage degeneration and arthritis, based on the measurement of load-induced electrical potentials from the surface of the cartilage during arthroscopic surgery, and non-invasively from the surface of the knee
Damon Smith	Labopharm Inc.	PROMOT ² E : development of novel protected micelle-oligonucleotide targeted therapeutic entities for effective gene silencing
Jean-Claude Tardif	Montreal Heart Institute/Université de Montréal	Development of prognostic biomarkers for high-risk complications in patients undergoing percutaneous coronary intervention following ST elevation acute myocardial infarction